Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

Lung cancer remains a leading cause of cancer death worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs), including those targeting programmed cell death protein-1 and its ligand (PD-1/PD-L1), have revolutionized the treatment l...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Solange, Paz-Ares, Luis, Herbst, Roy S, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305809/
https://www.ncbi.nlm.nih.gov/pubmed/35858709
http://dx.doi.org/10.1136/jitc-2022-004863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305809/
https://www.ncbi.nlm.nih.gov/pubmed/35858709
http://dx.doi.org/10.1136/jitc-2022-004863

Ejemplares similares